Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Product Development

Clinical Report: Ionis’ therapy for Angelman syndrome heading for Phase III

Plus: Data from Innovent, Agenus, Merck, Bayer and Orion

By Paul Bonanos, Director of Biopharma Intelligence, and Lauren Martz, Executive Director of Biopharma Intelligence
July 23, 2024 10:14 PM UTC

Weeks after Biogen declined an option for its therapy for Angelman syndrome, Ionis said new data from a Phase I/II study warrant the start of a Phase III trial next year.

The data for ION582 from Ionis Pharmaceuticals Inc. (NASDAQ:IONS) appear competitive with a rival antisense oligonucleotide from Ultragenyx Inc. (NASDAQ:RARE), which has also shown promise in a Phase I/II trial...

Get Unlimited Access
Continue reading with a free trial.
Start a Free TrialLog In
Or Purchase This Article

BCIQ Company Profiles

Agenus Inc.

Bayer AG

Innovent Biologics Inc.

Ionis Pharmaceuticals Inc.

Merck & Co. Inc.

Orion Therapeutics Inc.